OTHER SMARCA4-DEFICIENT MALIGNANT TUMORS (WITH PI APPROVAL)

Clinical trials for OTHER SMARCA4-DEFICIENT MALIGNANT TUMORS (WITH PI APPROVAL) explained in plain language.

Never miss a new study

Get alerted when new OTHER SMARCA4-DEFICIENT MALIGNANT TUMORS (WITH PI APPROVAL) trials appear

Sign up with your email to follow new studies for OTHER SMARCA4-DEFICIENT MALIGNANT TUMORS (WITH PI APPROVAL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New hope for kids with Ultra-Rare, aggressive cancers

Disease control Ongoing

This study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control rare, aggressive cancers in children and young adults. The trial is for patients whose cancers have returned or haven't responded to standard treatments. Researchers…

Matched conditions: OTHER SMARCA4-DEFICIENT MALIGNANT TUMORS (WITH PI APPROVAL)

Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated Mar 24, 2026 12:02 UTC

OTHER SMARCA4-DEFICIENT MALIGNANT TUMORS (WITH PI APPROVAL)

Get alerted when new OTHER SMARCA4-DEFICIENT MALIGNANT TUMORS (WITH PI APPROVAL) trials appear

New hope for kids with Ultra-Rare, aggressive cancers